Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.63 |
| ▸ | TUBB | P07437 | 1/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.63 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.63 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.63 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087104 | 0.90 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5906946 | 0.89 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5906950 | 0.89 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3000966 | 0.86 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1578409 | 0.83 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4088403 | 0.79 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2245487 | 0.78 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Indibulin SCHEMBL3165856 | 0.78 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Indibulin SCHEMBL29355017 | 0.78 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6269213 | 0.77 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004044-A1 | 3-glyoxylamideindoles for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6958348-B2 | 3-glyoxylamideindoles for treating cancer | SYNTA PHARMACEUTICALS CORP. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1427416-A2 | 3-GLYOXLYLAMIDEINDOLES FOR TREATING CANCER | Synta Pharmaceuticals Corporation (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030092751-A1 | 3-glyoxlylamideindoles for treating cancer | SBR PHARMACEUTICALS CORP. | 2003-05-15 | — | — | US | disclosed |
| WO-2003022280-A2 | 3-GLYOXLYLAMIDEINDOLES FOR TREATING CANCER | SYNTA PHARMACEUTICALS CORP. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004044-A1 | 3-glyoxylamideindoles for treating cancer | GLB1, SLC22A2, AGXT | TUBB4A 283/4885TUBB 176/4885TUBA3C 1131/4885 |
| US-20030092751-A1 | 3-glyoxlylamideindoles for treating cancer | GDI2, GOT2, TOP2B | TUBB4A 256/4885TUBB 105/4885TUBA3C 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.